Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_3
1
20%
Ph phase_1
2
40%
Ph phase_2
2
40%

Phase Distribution

2

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (40.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)

Trials by Status

completed480%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00112840
terminatedphase_2

Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy

NCT00076206
completedphase_1

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

NCT00483262
completedphase_2

Study Evaluating CCI-779 in Relapsing Multiple Sclerosis

NCT00228397
completedphase_3

Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma

NCT00065468

Clinical Trials (5)

Showing 5 of 5 trials
NCT00112840Phase 1

CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer

Completed
NCT00076206Phase 2

Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy

Terminated
NCT00483262Phase 1

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Completed
NCT00228397Phase 2

Study Evaluating CCI-779 in Relapsing Multiple Sclerosis

Completed
NCT00065468Phase 3

Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5